Therapeutic ranges of serum digoxin concentrations in patients with heart failure.
作者信息
Goldberger Zachary D, Goldberger Ary L
出版信息
Am J Cardiol. 2012 Jun 15;109(12):1818-21. doi: 10.1016/j.amjcard.2012.02.028. Epub 2012 Apr 11.
Abstract
摘要
相似文献
1
Therapeutic ranges of serum digoxin concentrations in patients with heart failure.心力衰竭患者血清地高辛浓度的治疗范围。
Am J Cardiol. 2012 Jun 15;109(12):1818-21. doi: 10.1016/j.amjcard.2012.02.028. Epub 2012 Apr 11.
2
Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data.
JAMA Intern Med. 2013 Sep 9;173(16):1552-4. doi: 10.1001/jamainternmed.2013.7756.
3
[Lower digitalis dosage in heart failure].[心力衰竭中较低的洋地黄剂量]
Tidsskr Nor Laegeforen. 2007 Apr 19;127(8):1053-4.
4
Controlling the effectiveness of digoxin.控制地高辛的疗效。
J Am Coll Cardiol. 2002 Aug 21;40(4):836; author reply 836-7. doi: 10.1016/s0735-1097(02)02018-1.
5
Lower serum digoxin concentrations in heart failure and reassessment of laboratory report forms.心力衰竭患者血清地高辛浓度降低及实验室报告表格的重新评估
Am J Med Sci. 2002 Jul;324(1):10-3. doi: 10.1097/00000441-200207000-00003.
6
Low-dose digoxin in patients with heart failure. Less toxic and at least as effective?
J Am Coll Cardiol. 2002 Mar 20;39(6):954-6. doi: 10.1016/s0735-1097(02)01710-2.
7
Optimal digoxin concentrations for patients with heart failure.
JAMA. 2003 May 28;289(20):2643; author reply 2643-4. doi: 10.1001/jama.289.20.2643-a.
8
Omeprazole does not modulate pharmacokinetic of digoxin in patients with heart failure.奥美拉唑对心力衰竭患者地高辛的药代动力学无调节作用。
Int J Cardiol. 2015 Jan 20;179:343-4. doi: 10.1016/j.ijcard.2014.11.062. Epub 2014 Nov 7.
9
Therapeutic digoxin level in chylous drainage with no detectable plasma digoxin level.
Chest. 1998 Nov;114(5):1482-4. doi: 10.1378/chest.114.5.1482.
10
[Therapeutic drug monitoring of digoxin in cardiac heart failure outpatients: comparisons of two analytical methods].
Farm Hosp. 2014 Jan 1;38(1):38-43. doi: 10.7399/FH.2014.38.1.1099.
引用本文的文献
1
Sex differences in pharmacotherapy for heart failure.心力衰竭药物治疗中的性别差异。
Ewha Med J. 2024 Jan;47(1):e3. doi: 10.12771/emj.2024.e3. Epub 2024 Jan 31.
2
New Monitoring Recommendations for Digoxin During the Last Decade Are Associated With Decreased Serum Digoxin Concentrations in Patient Samples.过去十年中关于地高辛的新监测建议与患者样本中血清地高辛浓度降低有关。
Basic Clin Pharmacol Toxicol. 2025 Aug;137(2):e70083. doi: 10.1111/bcpt.70083.
3
Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians.心力衰竭的利尿治疗：临床医生实用指南
J Clin Med. 2024 Jul 30;13(15):4470. doi: 10.3390/jcm13154470.
4
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南：心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2024 Jan 2;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017. Epub 2023 Nov 30.
5
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南：心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
6
Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.探索个体药物代谢特征的新方法，推进精准医学发展。
Drug Metab Dispos. 2023 Oct;51(10):1238-1253. doi: 10.1124/dmd.122.001066. Epub 2023 Jul 7.
7
Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line.哇巴因对替莫唑胺耐药（T98G）与替莫唑胺敏感（LN229）胶质母细胞瘤细胞系的显著不同作用。
Discov Oncol. 2023 Feb 25;14(1):27. doi: 10.1007/s12672-023-00633-2.
8
The impact of antiarrhythmics on human pulmonary arteries: Ex vivo characterization.抗心律失常药物对人肺动脉的影响：体外特性研究。
J Clin Transl Res. 2022 Jul 25;8(4):302-307. eCollection 2022 Aug 29.
9
Combinatorial Therapy of Cancer: Possible Advantages of Involving Modulators of Ionic Mechanisms.癌症的联合治疗：涉及离子机制调节剂的潜在优势
Cancers (Basel). 2022 May 30;14(11):2703. doi: 10.3390/cancers14112703.
10
Analysis of Intoxication, Rehospitalization, and One-year Survival of Heart Failure Patients Receiving Digoxin at Harapan Kita National Cardiovascular Center, Jakarta, Indonesia: A Cross Section-observational Study.印度尼西亚雅加达哈拉潘基塔国家心血管中心地高辛中毒、再入院和心力衰竭患者一年生存率的分析：一项横断面观察性研究。
Curr Drug Saf. 2023;18(2):246-252. doi: 10.2174/1574886317666220520114417.
本文引用的文献
1
Emergency hospitalizations for adverse drug events in older Americans.老年人因药物不良反应而紧急住院的情况。
N Engl J Med. 2011 Nov 24;365(21):2002-12. doi: 10.1056/NEJMsa1103053.
2
Dronedarone for atrial fibrillation: How does it compare with amiodarone?用于心房颤动的多非利特：与胺碘酮相比如何？
Cleve Clin J Med. 2011 Mar;78(3):179-85. doi: 10.3949/ccjm.78a.10049.
3
HFSA 2010 Comprehensive Heart Failure Practice Guideline.HFSA 2010 全面心力衰竭治疗指南。
J Card Fail. 2010 Jun;16(6):e1-194. doi: 10.1016/j.cardfail.2010.04.004.
4
Digoxin associates with mortality in ESRD.地高辛与 ESRD 患者的死亡率相关。
J Am Soc Nephrol. 2010 Sep;21(9):1550-9. doi: 10.1681/ASN.2009101047. Epub 2010 Jun 24.
5
Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.荟萃分析：β受体阻滞剂剂量、心率降低与心力衰竭患者的死亡情况
Ann Intern Med. 2009 Jun 2;150(11):784-94. doi: 10.7326/0003-4819-150-11-200906020-00006.
6
2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.2009年重点更新：美国心脏病学会基金会/美国心脏协会成人心力衰竭诊断与管理指南：美国心脏病学会基金会/美国心脏协会实践指南工作组报告：与国际心肺移植学会合作制定。
Circulation. 2009 Apr 14;119(14):1977-2016. doi: 10.1161/CIRCULATIONAHA.109.192064. Epub 2009 Mar 26.
7
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).《2008年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南》：欧洲心脏病学会2008年急性和慢性心力衰竭诊断与治疗特别工作组制定。与欧洲心脏病学会心力衰竭协会（HFA）合作编写，并得到欧洲重症医学学会（ESICM）认可。
Eur Heart J. 2008 Oct;29(19):2388-442. doi: 10.1093/eurheartj/ehn309. Epub 2008 Sep 17.
8
Declining public health burden of digoxin toxicity from 1991 to 2004.1991年至2004年期间地高辛中毒导致的公共卫生负担下降。
Clin Pharmacol Ther. 2008 Jul;84(1):90-4. doi: 10.1038/sj.clpt.6100458. Epub 2007 Dec 19.
9
Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure.慢性心力衰竭患者血清地高辛浓度处于低水平时，停用与继续使用地高辛的效果比较
Am J Cardiol. 2007 Jul 15;100(2):280-4. doi: 10.1016/j.amjcard.2007.02.099. Epub 2007 Jun 6.
10
Digoxin use and digoxin toxicity in the post-DIG trial era.地高辛试验后时代的地高辛使用与地高辛毒性
J Card Fail. 2006 Jun;12(5):343-6. doi: 10.1016/j.cardfail.2006.02.005.
Zotero 插件